

Proposed Project Scope

Pembrolizumab for Neoadjuvant Treatment of Stage III or IV Melanoma

Date: October 2023

Background and Rationale

CADTH received a request from public drug programs for a Non-Sponsored Reimbursement Review of pembrolizumab for neoadjuvant treatment of stage III or IV melanoma.

Table I: Policy Questions

Item	Policy Question
1	Should pembrolizumab be publicly reimbursed for neoadjuvant treatment of Stage III or IV melanoma?

Table II: Products Available in Canada

Product	Manufacturer
Pembrolizumab	Merck Canada Inc

Project Description

Table III: Project Scope

Criteria	Description
Population	Patients with stage III or IV melanoma
Intervention(s)	Pembrolizumab given both in the neoadjuvant and adjuvant settings
Comparators	Adjuvant pembrolizumab alone
Outcomes	Event-free survival, overall survival, response rate, and adverse events

Table IV: Research Questions

Item	Policy Question
1	What is the effectiveness of pembrolizumab for neoadjuvant treatment of Stage III or IV melanoma?
2	What are the harms associated with pembrolizumab for neoadjuvant treatment of Stage III or IV melanoma?
3	What is the expected cost of pembrolizumab for neoadjuvant treatment of Stage III or IV melanoma vs. other reimbursed regimens?

Key Project and Protocol Components

This project will follow the [Procedures for Non-Sponsored Reimbursement Reviews](#).

Status of the Document

This proposed project scope is being posted for information.